新辅助治疗联合经肛切除治疗T_(2～3)期直肠癌  

Advances of Neoadjuvant Therapy Combined with Transanal Resection in Stage T_(2-3) Rectal Cancer

作　　者：徐溯[1] 杨廷翰 汪晓东[1] 李立[1] 

机构地区：[1]四川大学华西医院胃肠外科中心,成都610041 [2]四川大学华西临床医学院,成都610041

出　　处：《中国普外基础与临床杂志》2010年第4期407-410,共4页Chinese Journal of Bases and Clinics In General Surgery

基　　金：四川省卫生厅科研课题(项目编号:080278)~~

摘　　要：目的介绍新辅助治疗(neoadjuvant therapy)联合经肛切除术在治疗T2～3期直肠癌中的应用和进展。方法收集国内、外关于新辅助治疗联合经肛切除术治疗T2～3期直肠癌的文献并进行分析和综述。结果对于经过严格选择的T2～3期直肠癌患者,采用新辅助治疗联合经肛手术可以有效地提高保肛率,减少并发症的发生。与仅进行手术而未行新辅助治疗的患者相比,复发率由17%～62%降到0～20%。结论经过严格选择的T2～3期直肠癌患者可从新辅助治疗联合经肛手术中受益。Objective To summarize the application and advancement of neoadjuvant therapy combined with transanal resection in stage T2-3 rectal cancer.Methods Domestic and abroad publications on the studies of neoadjuvant therapy combined with transanal resection in stage T2-3 rectal cancer in recent years were collected and reviewed.Results In selected patients with stage T2-3 rectal cancer,neoadjuvant therapy combined with transanal resection was efficacious in sphincter preservation and complications prevention.Compared with modality without chemoradiation,the recurrence rate had decreased from 17%-62% to 0-20%.Conclusion Selected patients with stage T2-3 rectal cancer can benefit from neoadjuvant chemoradiation combined with transanal resection.

关 键 词：新辅助放化疗 经肛手术 直肠癌 

分 类 号：R735.37[医药卫生—肿瘤]